Astellas and Pfizer have reported five-year follow-up outcomes from the open-label extension of the randomised Phase III ...

In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside Xtandi, reduced prostate cancer progression by 49%. The data ...

in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1 ...

On the regulatory front this year, a Pfizer spokesperson said the company anticipates three regulatory decisions in prostate cancer, colorectal cancer and non-Hodgkin lymphoma, as well as seven Phase ...

Oct 10 (Reuters) - Pfizer (PFE.N), opens new tab said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of advanced prostate cancer in a ...

Key ASCO GU Presentations Prostate Cancer Bladder Cancer Additional information on key Pfizer-sponsored abstracts at ASCO GU 2025, including date and time of presentation, follow in the chart below.